Who is sponsoring NCT04043065?

NCT04043065 is sponsored by University Hospital, Gentofte, Copenhagen.

What drugs are being tested in NCT04043065?

Interventions in NCT04043065: Liver-enriched antimicrobial peptide 2, Placebo.

What condition does NCT04043065 study?

NCT04043065 studies Type 2 Diabetes.

Is NCT04043065 still recruiting?

NCT04043065 is currently completed. Last updated 26 May 2021.

Last reviewed 2021-05-26 · How we verify

NCT04043065

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liver-enriched Antimicrobial Peptide 2

Completed EARLY_PHASE1 Last updated 26 May 2021

What this trial tests

EARLY_PHASE1 trial testing Liver-enriched antimicrobial peptide 2 in Type 2 Diabetes in 10 participants. Completed in 20 May 2019.

Timeline

28 January 2019

Primary endpoint
20 May 2019

20 May 2019

Quick facts

Lead sponsor	University Hospital, Gentofte, Copenhagen
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	10
Start date	28 January 2019
Primary completion	20 May 2019
Estimated completion	20 May 2019
Sites	1 location across Denmark

Drugs / interventions tested

Liver-enriched antimicrobial peptide 2 — full drug profile →
Placebo

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

University Hospital, Gentofte, Copenhagen

Who can join

Adults 18 to 25, male only, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to investigate the physiological importance of LEAP-2 in healthy volunteers focusing on its potential insulinotropic effects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antimicrobial peptide polymers: no escape to ESKAPE pathogens-a review.
Mukhopadhyay S, Bharath Prasad AS, Mehta CH, Nayak UY. · · 2020 · cited 48× · PMID 32737599 · DOI 10.1007/s11274-020-02907-1

Verify or expand the search:

Other trials of Liver-enriched antimicrobial peptide 2

Trials testing the same drug.

NCT04897984 — LEAP2 Kinetics in Healthy Individuals · EARLY_PHASE1 · completed
NCT04621409 — LEAP2 on Postprandial Glucose Metabolism and Food Intake · EARLY_PHASE1 · completed

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other University Hospital, Gentofte, Copenhagen trials

Trials by the same sponsor.

NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04043065 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
Last refreshed: 26 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04043065.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing